AKT1 and diabetes mellitus: Further animal experiments confirmed that compared with Vehicle-treated diabetic cognitive impairment mice, AVE 0991-treated diabetic cognitive impairment mice exhibited reduced p-AKT protein levels, and increased protein levels of FOXO1 and PACAP (Figure 6E).